Ultragenyx Pharmaceutical (RARE) Misses Q3 EPS by 4c

Ultragenyx Pharmaceutical (NASDAQ: RARE) reported Q3 EPS of ($0.50), $0.04 worse than the analyst estimate of ($0.46).

For earnings history and earnings-related data on Ultragenyx Pharmaceutical (RARE) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• GE Vernova (GEV) PT Raised to $1,185 at Jefferies
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says